The WISDOM Study has been redefining how we approach breast cancer screening — and the latest findings are practice-changing. In this session, Allison Stover Fiscalini, MPH, presents an update on WISDOM (Women Informed to Screen Depending on Measures of Risk), a landmark pragmatic trial that has enrolled more than 80,000 women across the United States. She will review the Phase 1 results published in JAMA in December 2025, which demonstrated that risk-based screening significantly reduced advanced-stage breast cancer diagnoses compared to standard annual mammography, and introduce the goals and design of WISDOM 2.0. Attendees will gain a clear understanding of how personalized risk assessment — incorporating genetics, breast density, family history, age, and lifestyle — can be translated into clinical practice, and what these findings mean for evolving screening guidelines and shared decision-making with patients.

Allison Stover Fiscalini, MPH, is the Executive Director of the Athena Breast Health Network and the WISDOM Study at the University of California, San Francisco (UCSF). A public health researcher and program leader with expertise in breast cancer screening, risk assessment, and precision medicine, she has played a central role in one of the most significant breast cancer screening trials in the United States.

As a key leader of the WISDOM Study — a landmark pragmatic trial that has enrolled more than 80,000 women — Fiscalini has helped drive a paradigm shift in how breast cancer screening is approached, moving from a one-size-fits-all model based on age to a personalized, risk-based framework that incorporates genetics, breast density, family history, and lifestyle factors. The study's Phase 1 results, published in JAMA in December 2025, demonstrated that risk-based screening reduced advanced-stage breast cancer diagnoses compared to standard annual mammography.

Fiscalini holds a Master of Public Health from the University of Washington and has co-authored numerous peer-reviewed publications in breast cancer screening, genomics, and patient-reported outcomes. She is currently leading enrollment for WISDOM 2.0, which aims to further refine risk prediction for aggressive breast cancers and expand access to personalized screening for women beginning at age 30.